Neuroharmonics

Neurotech platform using ultrasound technology to non-invasively treat and interface with the brain.

Woman sits under machine that wraps around her head while clinician stands next to her looking at computer

Neuroharmonics is built on a decade of the founders' research in biomedical ultrasound.

Noticing the inability to precisely target deep brain structures without invasive surgery, the company has designed and built a new platform to focus low-intensity ultrasound through the skull to influence brain circuits, guided by an MRI scan and computational models. The stimulation is non-ablative (it does not destroy tissue), and is built to be repeatable.

Ultrasound shows promise for treating neurological and psychiatric conditions, as well as a foundation for next-generation neuromodulation applications.

Once approved outside of the clinic, sessions are intended for an ordinary outpatient setting: no surgery, no implant, no anaesthesia and no head shaving. 

The Neuroharmonics journey so far: 

  • 2024: the company spun out of UCL.

Team

Dr Brad Treeby

Dr Brad Treeby

Co-founder and CEO

Antonio Stanziola

Dr Antonio Stanziola

Co-founder and Chief Technology Officer

Dr Michael Brown, Co-founder and Chief Scientific Officer

Dr Weng Sie Wong

Senior Business Manager

UCL Hawkes Institute

Dr Wong brings extensive experience of all aspects of university technology transfer activities from strategic IP management to licence negotiations and spinout formation.